Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFNt-modulated PBMC in IVF
NCT05775198Recruiting
- Sponsor
- Nadezhda Women's Health Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2026
- Modality
- Cytokines & Interferons, Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of autologous peripheral blood mononuclear cells + interferon tau in infertility (2 arms), sponsored by Nadezhda Women's Health Hospital. Primary endpoints: Rate of Implantation, Clinical Pregnancy Rate at 6 weeks and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
autologous peripheral blood mononuclear cells + interferon tau
03
Conditions
infertility
Beyond the preview
Go deeper on NCT05775198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775198.